ERBB2 and breast cancer: Remarkably, our study demonstrated that FASN inhibitors restored sensitivity to TZ in HER2 + BC cells with acquired TZ resistance, which is also consistent with previous research regarding the restoration of sensitivity of HER2 + BC to TZ and lapatinib after FASN inhibition (Vazquez-Martin et al. 2007).